<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of gout flares</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of gout flares</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of gout flares</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Angelo L Gaffo, MD, MsPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicola Dalbeth, MBChB, MD, FRACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A gout flare is intensely painful and disabling. Typically, a gout flare affects a single joint, although flares affecting multiple joints can occur. Without therapy, a gout flare usually resolves completely within a few days to several weeks, particularly in early disease. However, symptoms improve faster with treatment [<a href="#rid1">1</a>].</p><p>Flares recur in the great majority of patients. With more frequent episodes, flares may be more severe and prolonged, and asymptomatic periods become shorter.</p><p>The management of gout flares will be reviewed here. The approach to asymptomatic hyperuricemia; the pathophysiology, clinical manifestations, and diagnosis of gout; and the prevention of recurrent gout after resolution of the gout flares are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1669.html" rel="external">"Asymptomatic hyperuricemia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1673.html" rel="external">"Pathophysiology of gout"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1667.html" rel="external">"Clinical manifestations and diagnosis of gout"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout"</a>.)</p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-120058">(Related Pathway(s):  <a class="utd-content-120058" href="/pathway/120058?topicRef=1666&amp;source=see_link">Gout: Initial management of adults with a gout flare</a>.)</span></p><p></p><p class="headingAnchor" id="H11160517"><span class="h1">PRETREATMENT CONSIDERATIONS</span></p><p class="headingAnchor" id="H4164865092"><span class="h2">Exclude alternate diagnoses</span><span class="headingEndMark"> — </span>An alternative (or additional) cause of acute inflammatory arthritis (eg, infection) should be considered under the following circumstances:</p><p class="bulletIndent1"><span class="glyph">●</span>The current flare is atypical for the patient</p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of gout has not been established</p><p class="bulletIndent1"><span class="glyph">●</span>The flare occurs in a patient at high risk for infection</p><p></p><p>In patients who require arthrocentesis and synovial fluid analysis to exclude infection, we avoid oral, parenteral, and intraarticular glucocorticoids until the synovial fluid white blood cell count and gram stain are available. However, these conditions would not preclude treatment with a nonsteroidal antiinflammatory drug (NSAID) or <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>. The differential diagnosis and evaluation of gout is discussed separately. (See  <a class="medical medical_review" href="/d/html/1667.html" rel="external">"Clinical manifestations and diagnosis of gout", section on 'Differential diagnosis of a gout flare'</a>.)</p><p class="headingAnchor" id="H3953730880"><span class="h2">Initiate therapy quickly</span><span class="headingEndMark"> — </span>Once the diagnosis has been established and infection seems less likely, treatment should start as soon as possible after the patient perceives the beginning of a flare, preferably within hours of symptom onset. More rapid and complete resolution of symptoms occurs the earlier that treatment is introduced.</p><p class="headingAnchor" id="H1713614186"><span class="h2">Continue or initiate chronic therapies for gout</span><span class="headingEndMark"> — </span>During a gout flare, urate-lowering medication should be continued, without interruption. These medications may include <a class="drug drug_general" data-topicid="8439" href="/d/drug information/8439.html" rel="external">allopurinol</a>, <a class="drug drug_general" data-topicid="9079" href="/d/drug information/9079.html" rel="external">febuxostat</a>, <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a>, benzbromarone, or <a class="drug drug_general" data-topicid="16076" href="/d/drug information/16076.html" rel="external">pegloticase</a>. There is no benefit to temporary discontinuation of these medications. Moreover, subsequent reintroduction of urate-lowering therapies may precipitate another flare.</p><p>There is no contraindication to starting long-term urate-lowering therapies for gout during the treatment of a gout flare. The decision should be individualized depending on patient factors and a discussion about the indication for urate-lowering therapies should be initiated during the episode of the gout flare. (See  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout"</a>.)</p><p class="headingAnchor" id="H2674128356"><span class="h1">INITIAL THERAPY</span></p><p class="headingAnchor" id="H2518180783"><span class="h2">Selection of agent</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a>, nonsteroidal antiinflammatory drugs (NSAIDs), and systemic glucocorticoids are all effective treatment options and should be started as soon as possible after onset of the gout flare. Selection of an agent to treat an early flare will largely depend on the provider’s familiarity with these agents and the patient’s comorbidities (which may prevent the use of some of these drugs)  (<a class="graphic graphic_algorithm graphicRef121286" href="/d/graphic/121286.html" rel="external">algorithm 1</a>). Patient's familiarity, access, and prior successful use of a medication can also influence the initial choice.</p><p>However, glucocorticoids are increasingly favored by expert guideline panels as first-line therapy for gout flares [<a href="#rid2">2-4</a>].</p><p>We encourage patients to maintain a supply of gout flare medication at home to allow initiation of treatment at the first sign of flare.</p><p class="headingAnchor" id="H4057634266"><span class="h2">Glucocorticoids</span></p><p class="headingAnchor" id="H675161443"><span class="h3">Intraarticular glucocorticoids</span><span class="headingEndMark"> — </span>For patients with a gout flare affecting one or two joints, we suggest treatment with intraarticular glucocorticoids (eg, <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide) if the practitioner has sufficient expertise to deliver this treatment in a timely manner. Such treatment avoids complications associated with systemic therapy.</p><p>We use a single injection of <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide (40 mg for a large joint [eg, knee], 30 mg for a medium joint [eg, wrist, ankle, elbow], and 10 mg for a small joint). <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">Methylprednisolone</a> acetate may also be used<em> </em> (<a class="graphic graphic_table graphicRef115705" href="/d/graphic/115705.html" rel="external">table 1</a>).</p><p>If joint infection is suspected, synovial fluid culture should be used to exclude infection prior to treatment with intraarticular glucocorticoids. Septic arthritis and a gout flare can coexist; therefore, the possibility of septic arthritis should be considered, even in a patient with well-established gout.</p><p>In our experience, a single injection of intraarticular glucocorticoids is usually highly effective, and patients experience relief within 24 hours. However, published evidence supporting the use of intraarticular glucocorticoids is limited to small, open-label trials [<a href="#rid5">5</a>]. A 2013 systematic review noted that this practice has never been examined in a randomized study [<a href="#rid6">6</a>]. Evidence of effectiveness in other inflammatory arthritis, such as rheumatoid arthritis, also support its use in gout. Interarticular glucocorticoids should be avoided in patients with known or suspected septic arthritis. Other considerations, including complications and contraindications, are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7520.html" rel="external">"Use of glucocorticoids in the treatment of rheumatoid arthritis", section on 'Intraarticular therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7977.html" rel="external">"Joint aspiration or injection in adults: Complications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7985.html" rel="external">"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?"</a>.)</p><p></p><p class="headingAnchor" id="H3530051554"><span class="h3">Oral glucocorticoids</span><span class="headingEndMark"> — </span>For patients with a gout flare that affects multiple joints simultaneously or with monoarthritis when arthrocentesis is not feasible (eg, inaccessible joint, lack of available expertise), treatment with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 40 mg daily until the flare resolves is an option. Equivalent doses of <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> may also be used. Glucocorticoids may be administered through an intramuscular or intravenous route when oral administration is not feasible.</p><p>For most patients, we suggest tapering glucocorticoids over 7 to 10 days after the flare has resolved. For patients with a history of relapsing or refractory disease, we suggest extending the duration of the taper to 14 to 21 days.</p><p>Shorter glucocorticoid courses can be effective in many cases, mainly when the flare is treated within the first 48 to 72 hours since its onset. Glucocorticoid pack formulations are commonly used and can be effective in this setting. However, shorter glucocorticoid courses may increase the risk of rebound flares, particularly among patients with relapsing or refractory disease. Thus, the length of taper should be individualized and sometimes modified for any given patient.</p><p>Adverse effects associated with glucocorticoids are discussed separately. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p>Several randomized trials comparing glucocorticoids with NSAIDs for gout flares demonstrate that glucocorticoids are at least as efficacious as NSAIDs and may be associated with fewer serious adverse outcomes [<a href="#rid7">7-10</a>].</p><p class="headingAnchor" id="H1018664339"><span class="h3">Parenteral glucocorticoids</span><span class="headingEndMark"> — </span>In patients who are unable to take medications orally and who are not candidates for intraarticular glucocorticoid injection, we generally suggest treatment with intravenous or intramuscular glucocorticoids:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous</strong> – We suggest <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 20 mg administered intravenously twice daily. When the flare begins to resolve, the dose may be tapered over the next 7 to 10 days. When feasible, the patient may be transitioned to oral glucocorticoids to complete the taper.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intramuscular</strong> – We suggest <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetate 40 to 60 mg (or an equivalent dose of <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a>), which can be repeated every 48 hours until the flare has resolved. Tapering doses are not necessary.</p><p></p><p>Few randomized trials have adequately evaluated the benefit of systemic parenteral glucocorticoids [<a href="#rid10">10,11</a>]; the published studies and the few randomized trials have significant limitations in quality and strength of evidence [<a href="#rid12">12,13</a>]. A network meta-analysis of randomized trials found parenteral glucocorticoids appeared to have similar efficacy as other strategies used to treat gout flares [<a href="#rid14">14</a>].</p><p>We discourage the use of corticotropin (adrenocorticotropic hormone [ACTH]), although it has been reported to be efficacious for gout flare treatment. However, cost and availability considerations disfavor its use.</p><p class="headingAnchor" id="H3207050232"><span class="h2">Colchicine</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and efficacy</strong> – <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> has been used for centuries for the treatment of gout flares, but it has not been extensively studied in randomized trials [<a href="#rid15">15,16</a>]. However, the available studies imply that it is as effective as NSAIDs.</p><p></p><p class="bulletIndent1">In an open-label randomized trial of 399 patients with a gout flare, <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> and <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> were equally effective at pain reduction [<a href="#rid17">17</a>]. In another trial, more patients had a 50 percent reduction in pain at 24 hours with colchicine than those taking placebo (36 versus 16 percent) [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications</strong> – <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> is contraindicated in the presence of any degree of kidney or hepatic impairment in patients receiving a P-gp inhibitor  (<a class="graphic graphic_table graphicRef73326" href="/d/graphic/73326.html" rel="external">table 2</a>) or an agent that strongly reduces availability of the cytochrome P450 system component CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>) [<a href="#rid18">18-20</a>].</p><p></p><p class="bulletIndent1">We also avoid <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> in patients with kidney or hepatic impairment if they have recently (eg, within the past 14 days) completed treatment with medications that inhibit CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>) and/or the P-glycoprotein (P-gp) efflux pump  (<a class="graphic graphic_table graphicRef73326" href="/d/graphic/73326.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1">Among patients with chronic kidney disease, drugs that inhibit CYP3A4 or P-glycoprotein may further reduce clearance of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> by interfering with colchicine metabolism. These agents include some commonly used antibiotics such as <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, and <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>; antiretroviral drugs; and antihypertensive agents, including <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>. Concurrent use of these medications with colchicine may thus increase the risk of myelosuppression, and fatal pancytopenia may ensue [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Care should also be taken in combining use of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> with the wider array of less potent CYP3A4 inhibitors, including <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>, and grapefruit juice  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>), and drugs with potential for additive side effects, such as myotoxicity, in combination with a statin or fibrate (eg, <a class="drug drug_general" data-topicid="8488" href="/d/drug information/8488.html" rel="external">gemfibrozil</a>).</p><p></p><p class="bulletIndent1">Guidance for dosing of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> in such patients is discussed below.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and dosing</strong> – We suggest an initial dose of 1.2 mg of oral <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>. One hour later, another 0.6 mg should be administered for a total dose on the first day of therapy of 1.8 mg [<a href="#rid16">16,18,20</a>]. Subsequently, the colchicine dose should be reduced to 0.6 mg twice daily until 48 hours after resolution of the flare.</p><p></p><p class="bulletIndent1">Where 0.5 mg is the only available form, an initial dose of 1 mg may be used, followed by 0.5 mg one hour later for a total of 1.5 mg for the first day of therapy. Subsequently, the <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> dose may be reduced to 0.5 mg twice daily until 48 hours after the resolution of the flare.</p><p></p><p class="bulletIndent1">In patients already receiving <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> prophylaxis (0.6 or 0.5 mg once to twice daily) at the time of their flare, this regimen is used in place of the usual prophylactic dose, which may be resumed once the flare has been treated.</p><p></p><p class="bulletIndent1">When the gout flare fails to respond to three days of low-dose <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, an alternative antiinflammatory agent (eg, glucocorticoids, NSAIDs) should be added to the treatment regimen. (See <a class="local">'Nonsteroidal antiinflammatory drugs (NSAIDs)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Precautions</strong> – We discourage increasing <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> beyond standard doses. In a randomized study of patients with a gout flare, colchicine 1.8 mg was found to be equally effective as high-dose colchicine (4.8 mg) at reducing pain by at least 50 percent in 24 hours (response rate 37.8 versus 32.7 percent) [<a href="#rid16">16</a>]. However, the high dose was associated with an increased risk of adverse events, including diarrhea and emesis.</p><p></p><p class="bulletIndent1">We do not administer <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> intravenously, and we strongly advise against such use because of the risk of serious adverse effects, including death, which are associated with the intravenous administration of this drug. Due to this concern, in many countries, an intravenous form of colchicine is no longer available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modified dosing</strong> – In patients with multiple factors that may potentially increase <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> exposure beyond safe levels, we suggest using no more than 0.3 mg on day of flare. Subsequently, we suggest administering no more than 0.3 mg every three days until the flare has resolved. These particularly high-risk groups include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients on <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> prophylaxis within the past 14 days, with normal kidney and hepatic function, who have taken a strong CYP3A4 inhibitor  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>) or a drug that inhibits P-gp  (<a class="graphic graphic_table graphicRef73326" href="/d/graphic/73326.html" rel="external">table 2</a>) within the last 14 days [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients on <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> prophylaxis within the past 14 days, with any kidney or hepatic impairment, who have taken a moderate CYP3A4 inhibitor  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>) within the last 14 days.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients regardless of recent <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> use, with advanced kidney or hepatic impairment (creatinine clearance of &lt;30 mL/minute or Child-Pugh class C cirrhosis or equivalent, respectively) who are not receiving any interacting medications. Patients with kidney or hepatic impairment who are receiving an interacting medication should not receive colchicine.</p><p></p><p class="bulletIndent1">Additional factors that may affect dosing and further mandate a need for reduced dose and frequency of administration or avoidance of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> altogether include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional drug interactions beyond those recognized from drugs that are moderate or strong CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>) or P-gp  (<a class="graphic graphic_table graphicRef73326" href="/d/graphic/73326.html" rel="external">table 2</a>) inhibitors (eg, additive myotoxicity with combined use of statin and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>). The <a class="external" href="/drug-interactions">drug interactions program</a> available within UpToDate should be consulted for additional information.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Advanced age. (See <a class="local">'Older adults'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic ill health and debility.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of more than one medication that can interact with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Combinations of multiple factors, some of which alone may not be problematic but which in combination can increase risk of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> accumulation.</p><p></p><p class="bulletIndent1"><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2014%2F022352s017lbl.pdf&amp;token=zT7UpQk75MtSIprTTQwcGc%2FhggB4UAeaUP3t5Pe3aQ8woxCoTlVu0yhAlTNp5xFz5q7pARDisX9ISPmRlos3ej4V2H8Ihkqk6CebZMjYlbA%3D&amp;TOPIC_ID=1666" target="_blank">Dosing guidelines</a> for <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> have been proposed by one manufacturer for those patients with normal kidney and hepatic function who are receiving interacting agents or who have received them within 14 days, and guidelines for colchicine administration in patients with kidney or hepatic impairment who are not using an interacting medication have also been described [<a href="#rid20">20</a>]. However, formal guidelines for dose adjustment in patients with multiple interacting factors have not been established, and our approach, which is based upon our personal experience, may differ in some limited respects from the manufacturer's guidelines.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> – All patients using <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> should be advised about the potential for and management of adverse events on colchicine therapy. Patients who develop diarrhea, emesis, dysesthesias, or weakness should be instructed to stop therapy immediately. Close monitoring of pertinent organ function and clinical status may be required and should be individualized depending upon the patient’s clinical status.</p><p></p><p class="bulletIndent1">Gastrointestinal symptoms (diarrhea and abdominal cramping, as well as abdominal pain, nausea, and vomiting) are the most common adverse reactions to <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> administration [<a href="#rid20">20</a>]. Colchicine was reported to have more side effects than <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> in a clinical trial, with higher frequencies of diarrhea and headaches [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">Colchicine-induced neuromyopathy is a potential complication of chronic therapy, particularly in patients with a reduced creatinine clearance. It should be suspected in patients who complain of paresthesias, numbness, and/or weakness. Most cases occur in patients treated with daily low-dose <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> for months to years. Complaints of weakness and functional decline while taking colchicine should prompt a careful neurologic examination, laboratory evaluation including a serum creatine kinase, and empirical drug discontinuation. (See  <a class="medical medical_review" href="/d/html/5166.html" rel="external">"Drug-induced myopathies", section on 'Colchicine'</a>.)</p><p></p><p class="bulletIndent1">Severe <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> toxicities may also occur, including cytopenias, rhabdomyolysis or myopathy, peripheral neuropathy, liver failure, or severe cutaneous eruption. Severe outcomes are rare among patients who receive a short course of colchicine for a gout flare [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> is a lipophilic alkaloid with a narrow therapeutic margin, and therefore toxicity can occur without markedly elevated doses. Caution should be taken to avoid unintended intoxication.</p><p></p><p class="bulletIndent1">Patients receiving <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> should have their medication regimen regularly analyzed for drug interactions, particularly when initiating and adjusting therapy; this may be done by use of the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="headingAnchor" id="H3636739958"><span class="h2">Nonsteroidal antiinflammatory drugs (NSAIDs)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications and contraindications for NSAIDs</strong> – We suggest NSAIDs for treatment of a gout flare in younger patients (less than 60 years old) with neither kidney nor cardiovascular comorbidities or active gastrointestinal disease for whom NSAID use is generally well tolerated.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">Aspirin</a> is not used to treat gout flares, because low-dose salicylates induce kidney retention of uric acid [<a href="#rid23">23-27</a>]. However, low-dose aspirin used for cardiovascular prophylaxis should be continued during the treatment of a gout flare despite this effect [<a href="#rid25">25,26</a>]. Other important contraindications to NSAIDs are discussed separately.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration and choice of NSAID</strong> – We suggest <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> (500 mg twice daily) or <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> (50 mg three times daily). Other orally administered NSAIDs (and initial doses) that may be used include <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> (800 mg three times daily), <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> (50 mg two to three times daily), <a class="drug drug_general" data-topicid="10295" href="/d/drug information/10295.html" rel="external">meloxicam</a> (15 mg daily), and <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> (200 mg twice daily; alternatively, some experts treat with a single initial dose of 400 mg followed by 200 mg twice daily)  (<a class="graphic graphic_table graphicRef70067" href="/d/graphic/70067.html" rel="external">table 4</a>) [<a href="#rid28">28</a>]. A number of trials have compared different NSAIDs with each other, without any apparent differences in efficacy [<a href="#rid12">12,28-33</a>]. For example, in one randomized trial, treatment with high doses of celecoxib (a single dose of 800 mg followed by 400 mg twice daily) was as effective as indomethacin (50 mg three times daily) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">NSAIDs are most effective when treatment is initiated within 48 hours of the onset of symptoms. The dose may be reduced after a significant decrease in symptoms has occurred, but the frequency of dosing should be maintained for several more days for optimal antiinflammatory effect.</p><p></p><p class="bulletIndent1">NSAIDs may be discontinued a few days after clinical signs have completely resolved. Typically, the total duration of NSAID therapy for a gout flare is 7 to 10 days. Delayed therapy may make the flare less responsive and require a longer treatment course.</p><p></p><p class="bulletIndent1">Nonselective NSAIDs of all types are inexpensive and readily available to patients at the onset of a flare (some without a prescription), and short courses are probably as effective and safe as other agents [<a href="#rid12">12,17,29-33</a>] for this indication [<a href="#rid12">12,28,31-33</a>]. Patients should not be treated concurrently with more than one NSAID and should be queried regarding their medications (including over-the-counter therapies) to avoid such unintended use. Combination NSAIDs with glucocorticoids should also be avoided where possible due to the risk of peptic ulcer disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy of NSAIDs</strong> – In our experience, complete or nearly complete resolution of the pain and disability of a gout flare typically occurs within several days to one week.</p><p></p><p class="bulletIndent1">There are relatively few high-quality randomized trials of NSAIDs for gout flares [<a href="#rid12">12,28,34,35</a>]. A randomized open-label trial of 399 participants with gout flares compared <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> 750 mg oral dose followed by 250 mg every eight hours for seven days with low-dose <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> 0.5 mg three times daily for four days; at seven days, there was no difference in pain intensity, but naproxen caused fewer side effects [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">Several randomized trials comparing glucocorticoids with NSAID therapy for gout flare indicate similar benefit, although glucocorticoids may have fewer adverse effects, particularly in comparison with <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid7">7-10</a>].</p><p></p><p class="headingAnchor" id="H2203281396"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>Patients should be continued on oral or parenteral glucocorticoid treatment for the duration of the flare, although treatments may be tapered once a significant reduction in symptoms is achieved.</p><p>For most patients, we suggest tapering glucocorticoids over 7 to 10 days. For patients with a history of relapsing or refractory disease, we suggest extending the duration of the taper to 14 to 21 days.</p><p>The duration of therapy for a gout flare may range from only a few days (eg, in a patient treated within hours of symptom onset) to several weeks (eg, in a patient with a severe or polyarticular flare or begun on treatment after four or five days of symptoms). Many patients require antiinflammatory treatment for no more than 7 to 10 days if begun on therapy within 12 to 36 hours of symptom onset.</p><p>NSAIDs may be discontinued a few days after clinical signs have completely resolved. Typically, the total duration of NSAID therapy for a gout flare is 7 to 10 days. Delayed therapy may make the flare less responsive, and require a longer treatment course.</p><p class="headingAnchor" id="H12718923"><span class="h1">SPECIAL CIRCUMSTANCES</span></p><p class="headingAnchor" id="H17640260"><span class="h2">Patients on anticoagulation</span><span class="headingEndMark"> — </span>In patients on anticoagulants, we use one of the following approaches:</p><p class="bulletIndent1"><span class="glyph">●</span>When feasible, we suggest using <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, given its lack of effect on blood clotting. (See <a class="local">'Colchicine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> is contraindicated, oral glucocorticoids can be used (see <a class="local">'Oral glucocorticoids'</a> above). Caution and closer monitoring should be exercised if there is a history of peptic ulcer disease or gastrointestinal bleeding.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When oral glucocorticoids are contraindicated, a highly experienced clinician can safely inject glucocorticoids into the joint of a patient on anticoagulation. Care is necessary to avoid a hemarthrosis, although in our experience, this complication is very rare. (See <a class="local">'Intraarticular glucocorticoids'</a> above and  <a class="medical medical_review" href="/d/html/7986.html" rel="external">"Joint aspiration or injection in adults: Technique and indications", section on 'Approach to the patient on anticoagulants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When both <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> and glucocorticoids are contraindicated, patients may be managed with <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a>, which lacks the antiplatelet effect of the nonselective nonsteroidal antiinflammatory drugs (NSAIDs) but retains some potential for gastrointestinal toxicity. (See  <a class="medical medical_review" href="/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs", section on 'Reduction in gastroduodenal toxicity'</a> and  <a class="medical medical_review" href="/d/html/7992.html" rel="external">"Overview of COX-2 selective NSAIDs", section on 'Lack of platelet inhibition and use during anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When all standard therapies (ie, <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, glucocorticoids, NSAIDs) are contraindicated, patients may be managed with a short-acting interleukin 1 (IL-1) inhibitor such as <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>. (See <a class="local">'Resistant or refractory disease'</a> below.)</p><p></p><p class="headingAnchor" id="H12719033"><span class="h2">Older adults</span><span class="headingEndMark"> — </span>A systematic review suggested that all of the antiinflammatory agents discussed above are efficacious in older patients [<a href="#rid36">36</a>]. However, the use of these agents is complicated by the greater prevalence of comorbidities, including kidney dysfunction, which may preclude the use of NSAIDs or <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid37">37,38</a>]. Some caveats regarding the choice of therapy in older adults include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Colchicine</strong> – <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> myopathy and peripheral neuropathy can be subtle in older adults, although brief courses (eg, less than a week) for gout flares should not be associated with these complications. In case of longer courses or frequent use, complaints of weakness and functional decline while taking colchicine should prompt a careful neurologic examination, laboratory evaluation including a serum creatine kinase, and empirical drug discontinuation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>NSAIDs</strong> – Contraindications to the use of NSAIDs that are of particular concern in older adults include the presence of heart failure, kidney dysfunction, or gastrointestinal disease. (See <a class="local">'Nonsteroidal antiinflammatory drugs (NSAIDs)'</a> above.)</p><p></p><p class="bulletIndent1">In the absence of such contraindications, we still avoid the use of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> in older adults because of the greater risk of adverse effects with this medication compared with other NSAIDs [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – Brief courses of oral glucocorticoids are generally tolerated in patients in whom NSAIDs or <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> may pose an increased risk. (See <a class="local">'Oral glucocorticoids'</a> above.)</p><p></p><p>General principles and special concerns in prescribing drugs in this population are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/3013.html" rel="external">"Drug prescribing for older adults"</a>.)</p><p class="headingAnchor" id="H74454777"><span class="h2">End-stage kidney disease and transplantation</span><span class="headingEndMark"> — </span>We generally treat patients with advanced chronic kidney disease or end-stage kidney disease requiring maintenance dialysis with oral or intraarticular glucocorticoids. (See <a class="local">'Oral glucocorticoids'</a> above.)</p><p>When glucocorticoids are contraindicated, we modify treatment as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic hemodialysis</strong> – In patients on chronic hemodialysis, NSAIDs may be used as an alternative to glucocorticoids, particularly in patients with milder gout flares in whom lower doses and shorter courses can be employed (see <a class="local">'Nonsteroidal antiinflammatory drugs (NSAIDs)'</a> above). However, patients on hemodialysis may have an increased risk of gastrointestinal toxicity [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> is generally avoided in hemodialysis patients with gout flares because it is not removed by dialysis, and therefore these patients have a heightened risk of colchicine toxicity. (See <a class="local">'Colchicine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease</strong> – In patients with residual kidney function, including patients on peritoneal dialysis, NSAIDs should be avoided because of the risk of worsening kidney function; any use of NSAIDs in this setting should only be done in consultation with the patient's nephrologist. (See  <a class="medical medical_review" href="/d/html/7230.html" rel="external">"NSAIDs: Acute kidney injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kidney transplant</strong> – Gout flares in organ transplant recipients should only be managed by clinicians experienced with these clinical problems because of the complexities of management due to reduced uric acid excretion and because of the use of calcineurin inhibitors. Oral glucocorticoids are generally the preferred medication. Treatment in this setting is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7297.html" rel="external">"Kidney transplantation in adults: Hyperuricemia and gout in kidney transplant recipients", section on 'Selection of initial antiinflammatory therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1731349740"><span class="h2">Pregnancy and lactation</span><span class="headingEndMark"> — </span>Gout flares are exceedingly uncommon during pregnancy and lactation, paralleling the low prevalence of hyperuricemia in women of childbearing age in most populations (see  <a class="medical medical_review" href="/d/html/1669.html" rel="external">"Asymptomatic hyperuricemia", section on 'Epidemiology'</a>). Thus, the occurrence of an acute inflammatory arthritis resembling gout during pregnancy or breastfeeding should direct attention to the exclusion of alternative diagnoses, such as septic arthritis. (See  <a class="medical medical_review" href="/d/html/1667.html" rel="external">"Clinical manifestations and diagnosis of gout", section on 'Differential diagnosis'</a>.)</p><p>Despite its rarity, gout flares during pregnancy and lactation have been reported among women with familial juvenile hyperuricemic nephropathy [<a href="#rid41">41,42</a>] (see  <a class="medical medical_review" href="/d/html/1685.html" rel="external">"Autosomal dominant tubulointerstitial kidney disease", section on 'ADTKD due to UMOD pathogenic variants'</a>), unspecified "kidney impairment," and gestational diabetes [<a href="#rid43">43</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – In pregnant women with a gout flare, we generally use oral glucocorticoid therapy (see <a class="local">'Oral glucocorticoids'</a> above). In a patient with recurrent flares during pregnancy or breastfeeding, we use daily low-dose glucocorticoids for prophylaxis, given the need to avoid both <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> and NSAIDs.</p><p></p><p class="bulletIndent1">The use of NSAIDs is limited to the first 20 weeks of gestation, and short-term use of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> could be an option in pregnant women when glucocorticoids are contraindicated. (See <a class="local">'Nonsteroidal antiinflammatory drugs (NSAIDs)'</a> above.)</p><p></p><p class="bulletIndent1">Potential contraindications to glucocorticoids in such patients include poorly controlled hypertension or diabetes, in addition to other usual concerns.</p><p></p><p class="bulletIndent1">We also employ symptomatic treatment measures, such as icing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactation</strong> – In breastfeeding women, we use either glucocorticoids or NSAID therapy (see <a class="local">'Oral glucocorticoids'</a> above and <a class="local">'Nonsteroidal antiinflammatory drugs (NSAIDs)'</a> above) while continuing to avoid the use of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>.</p><p></p><p>Although antiinflammatory doses of an NSAID (eg, <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>, <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a>, or <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>) have been effective in some pregnant patients with a gout flare, use of NSAIDs is limited to the first two trimesters of pregnancy because of concerns about NSAID-induced premature closure of the ductus arteriosus later in pregnancy. NSAID therapy should also be withheld during pregnancy in the presence of impaired kidney function. The use of NSAIDs during pregnancy and lactation is described in detail separately. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'NSAIDs'</a>.)</p><p>Studies of <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> in pregnant and breastfeeding patients with familial Mediterranean fever or pericardial diseases have not found increased adverse effects with its use [<a href="#rid44">44,45</a>]. However, there are reports of colchicine in breast milk and chromosomal damage associated with colchicine exposure [<a href="#rid45">45-47</a>].</p><p class="headingAnchor" id="H12"><span class="h1">RESISTANT OR REFRACTORY DISEASE</span></p><p class="headingAnchor" id="H2289773226"><span class="h2">Reassess the diagnosis</span><span class="headingEndMark"> — </span>In patients who fail to respond to therapy, we reevaluate the diagnosis and assess adherence. Arthrocentesis may be required to exclude other causes of a flare of acute inflammatory arthritis, including infection, if joint aspiration was not already performed during the gout flare.</p><p class="headingAnchor" id="H2581702338"><span class="h2">Rebound flare</span><span class="headingEndMark"> — </span>If the diagnosis and adherence are confirmed, we consider the possibility of a “rebound” gout flare, which may occur if glucocorticoids are tapered too quickly (eg, less than five days). If rebound flare seems likely, we increase glucocorticoids back to the last effective dose and then resume the taper over two to three weeks.</p><p class="headingAnchor" id="H2105138066"><span class="h2">Partial response</span><span class="headingEndMark"> — </span>In patients who have had gradual improvement in their symptoms, but have failed to return to their premorbid baseline, treatment may need to be extended for up to four weeks. This is more common among patients who started treatment several days after the start of the gout flare.</p><p class="headingAnchor" id="H1018044771"><span class="h2">Resistant disease</span><span class="headingEndMark"> — </span>In patients who fail to respond after three days of treatment with <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> or nonsteroidal antiinflammatory drugs (NSAIDs), we would transition the patient to oral glucocorticoids. For patients who have persistent disease affecting only one or two joints, intraarticular glucocorticoids are an option, if this intervention is available locally.</p><p class="headingAnchor" id="H3775182122"><span class="h2">Refractory disease</span><span class="headingEndMark"> — </span>In patients who fail to respond to standard therapies, including systemic glucocorticoids, interleukin 1 (IL-1) blockade is an important option.</p><p class="headingAnchor" id="H12719329"><span class="h3">Interleukin 1 blockade</span><span class="headingEndMark"> — </span>IL-1 is an important mediator of gouty inflammation and a therapeutic target in gout flares [<a href="#rid48">48</a>]. Thus, agents inhibiting IL-1 action are an effective treatment for gout flares (see  <a class="medical medical_review" href="/d/html/1673.html" rel="external">"Pathophysiology of gout"</a>).</p><p class="headingAnchor" id="H1509938157"><span class="h4">Anakinra</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> (100 mg daily, administered subcutaneously daily until flare resolution) is the preferred IL-1 antagonist for use in a gout flare because of its short half-life. (See  <a class="medical medical_review" href="/d/html/7966.html" rel="external">"Overview of biologic agents in the rheumatic diseases", section on 'IL-1 inhibition'</a>.)</p><p>Randomized trials have demonstrated that <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> is as effective as standard of care therapies for the treatment of gout flares, although there may be an increased risk of rebound flares.</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial of 88 patients with a crystal-proven gout flare, <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> (100 mg daily for five consecutive days) was associated with similar short-term improvements in pain, tenderness, and swelling compared with standard of care therapies (eg, <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, oral glucocorticoids <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a>) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another randomized trial of 165 patients with a gout flare who were not candidates for NSAID or <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> therapy, <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> in doses of 100 to 200 mg daily provided similar reductions in pain as a single 40 mg injection of intramuscular <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> after 24 to 72 hours [<a href="#rid50">50</a>].</p><p></p><p class="headingAnchor" id="H968008176"><span class="h4">Canakinumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">Canakinumab</a> has been approved in the European Union and the United States for treatment of patients who have at least three flares annually that cannot be managed with other treatment options [<a href="#rid51">51,52</a>]. Canakinumab is also effective for gout prophylaxis. (See  <a class="medical medical_review" href="/d/html/1672.html" rel="external">"Pharmacologic urate-lowering therapy and treatment of tophi in patients with gout", section on 'Prophylaxis during initiation of urate-lowering therapy'</a>.)</p><p>Two randomized trials comprising 456 patients with gout flare demonstrated that <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> 150 mg was associated with greater reductions in pain at 72 hours compared with intramuscular <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetate [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H351308303"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112193.html" rel="external">"Society guideline links: Gout and other crystal disorders"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15395.html" rel="external">"Patient education: Gout (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/514.html" rel="external">"Patient education: Gout (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretreatment considerations</strong> – Early treatment of a gout flare leads to more rapid and complete resolution of the flare.</p><p></p><p class="bulletIndent1">However, gout and septic arthritis may present similarly. Glucocorticoids should be avoided until septic arthritis can be reasonably excluded. (See <a class="local">'Pretreatment considerations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of gout flare</strong> – For patients with a first or infrequent recurrent gout flare affecting one to two joints, we suggest intraarticular glucocorticoids if this treatment can be delivered in a timely manner (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). When using intraarticular glucocorticoids, we use <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetate (40 mg for a large joint; 20 mg for a medium joint). Such treatment is highly effective with a single dose and avoids complications associated with systemic therapy.</p><p></p><p class="bulletIndent1">For all other patients (including when intraarticular glucocorticoids are not available), systemic nonsteroidal antiinflammatory drugs (NSAIDs), <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, or glucocorticoids are alternatives to intraarticular therapy. Patient factors, prior experience, and availability should guide the choice of therapy. (See <a class="local">'Initial therapy'</a> above.)</p><p></p><p class="bulletIndent1">Guidance for dosing and administration include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – We use <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 40 mg daily until the flare resolves. Intravenous <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 20 mg twice daily or intramuscular <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetate 40 to 60 mg every two days are alternatives for patients who cannot take oral medications. Both should be continued until flare resolution.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> – On the first day of therapy, 1.2 mg of oral colchicine is followed one hour later by 0.6 mg. On subsequent days, colchicine 0.6 mg twice daily should be administered until 48 hours following the flare. Colchicine is contraindicated in the presence of any degree of kidney or hepatic impairment in patients receiving a P-glycoprotein (P-gp) inhibitor  (<a class="graphic graphic_table graphicRef73326" href="/d/graphic/73326.html" rel="external">table 2</a>) or an agent that strongly reduces availability of the cytochrome P450 system component CYP3A4.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> most commonly causes gastrointestinal symptoms but also may be associated with neuropathy, cytopenia, myopathy, liver failure, and rash.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">Colchicine</a> may need to be adjusted or avoided in patients with impaired liver or kidney function and in patients taking drugs that impact the cytochrome P450 system. (See <a class="local">'Colchicine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>NSAIDs</strong> – We use <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> 500 mg twice daily or <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> 50 mg three times daily until a few days after the flare has resolved. NSAIDs should be avoided in older patients and others who are at higher risk of the kidney, cardiovascular, and gastrointestinal side effects of NSAIDs (See <a class="local">'Nonsteroidal antiinflammatory drugs (NSAIDs)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special considerations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients on anticoagulation</strong> – In patients taking anticoagulation, we use <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> or oral glucocorticoids to avoid increasing the risk of bleeding that may occur with NSAIDs. An experienced provider may also be able to safely inject one or two joints with intraarticular glucocorticoids. (See <a class="local">'Patients on anticoagulation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Older adults</strong> – For older adults, we typically use oral glucocorticoids to manage an acute flare. Older adults are often intolerant of both NSAIDs and <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>. (See <a class="local">'Older adults'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with chronic kidney disease</strong> – In patients with impaired kidney function, we use glucocorticoids and avoid <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> and NSAIDs. In patients on chronic hemodialysis, NSAIDs may be used as an alternative to glucocorticoids. (See <a class="local">'End-stage kidney disease and transplantation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnant patients</strong> – In women who are pregnant or breastfeeding, we suggest managing gout flares with glucocorticoids. NSAIDs should be avoided after 20 weeks of gestation but may be used beforehand or in women who are breastfeeding. (See <a class="local">'Pregnancy and lactation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistant gout flares</strong> – In patients who fail to respond to two or three days of treatment with NSAIDS or <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a>, we would initiate treatment with glucocorticoids. Intraarticular glucocorticoids may be appropriate in patients with only one or two affected joints. (See <a class="local">'Oral glucocorticoids'</a> above and <a class="local">'Parenteral glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory gout flares</strong> – In patients who are refractory to standard therapies, options include interleukin 1 (IL-1) inhibition (ie, <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> 100 mg subcutaneously daily until flare resolution) or one dose of <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> 150 mg subcutaneously. (See <a class="local">'Interleukin 1 blockade'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prolonged therapy</strong> – Patients who have had a partial response or experience a rebound flare after an initial response may need longer courses of therapy. This includes patients in whom treatment is delayed and patients who have persistent symptoms despite treatment. (See <a class="local">'Resistant or refractory disease'</a> above.)</p><p></p><p class="headingAnchor" id="H826102640"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Michael A Becker, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mikuls TR. Gout. N Engl J Med 2022; 387:1877.</a></li><li><a class="nounderline abstract_t">Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64:1447.</a></li><li><a class="nounderline abstract_t">Qaseem A, Harris RP, Forciea MA, Clinical Guidelines Committee of the American College of Physicians. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2017; 166:58.</a></li><li><a class="nounderline abstract_t">Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76:29.</a></li><li><a class="nounderline abstract_t">Fernández C, Noguera R, González JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26:2285.</a></li><li><a class="nounderline abstract_t">Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013; :CD009920.</a></li><li><a class="nounderline abstract_t">Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008; 371:1854.</a></li><li><a class="nounderline abstract_t">Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007; 49:670.</a></li><li><a class="nounderline abstract_t">Rainer TH, Cheng CH, Janssens HJ, et al. Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. Ann Intern Med 2016; 164:464.</a></li><li><a class="nounderline abstract_t">Zhang YK, Yang H, Zhang JY, et al. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract 2014; 68:633.</a></li><li><a class="nounderline abstract_t">Janssens HJ, Lucassen PL, Van de Laar FA, et al. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008; :CD005521.</a></li><li><a class="nounderline abstract_t">Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review. Rheumatology (Oxford) 2006; 45:1422.</a></li><li><a class="nounderline abstract_t">Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19:329.</a></li><li><a class="nounderline abstract_t">Zeng L, Qasim A, Neogi T, et al. Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis. Arthritis Care Res (Hoboken) 2021; 73:755.</a></li><li><a class="nounderline abstract_t">Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17:301.</a></li><li><a class="nounderline abstract_t">Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62:1060.</a></li><li><a class="nounderline abstract_t">Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis 2020; 79:276.</a></li><li><a class="nounderline abstract_t">Colchicine and other drugs for gout. Med Lett Drugs Ther 2009; 51:93.</a></li><li><a class="nounderline abstract_t">Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum 2009; 38:411.</a></li><li class="breakAll">Colcrys (colchicine, USP) tablets, for oral use. US Food and Drug Administration (FDA) approved product information. Revised November 2012. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022352s017lbl.pdf (Accessed on April 12, 2019).</li><li><a class="nounderline abstract_t">Hung IF, Wu AK, Cheng VC, et al. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis 2005; 41:291.</a></li><li><a class="nounderline abstract_t">Bouquié R, Deslandes G, Renaud C, et al. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol 2011; 17:28.</a></li><li><a class="nounderline abstract_t">Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest 1959; 38:1298.</a></li><li><a class="nounderline abstract_t">Yu TF, Dayton PG, Gutman AB. Mutual suppression of the uricosuric effects of sulfinpyrazone and salicylate: A study in interactions between drugs. J Clin Invest 1963; 42:1330.</a></li><li><a class="nounderline abstract_t">Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000; 43:103.</a></li><li><a class="nounderline abstract_t">Segal R, Lubart E, Leibovitz A, et al. Renal effects of low dose aspirin in elderly patients. Isr Med Assoc J 2006; 8:679.</a></li><li><a class="nounderline abstract_t">Zhang Y, Neogi T, Chen C, et al. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 2014; 73:385.</a></li><li><a class="nounderline abstract_t">Schumacher HR, Berger MF, Li-Yu J, et al. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 2012; 39:1859.</a></li><li><a class="nounderline abstract_t">Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324:1488.</a></li><li><a class="nounderline abstract_t">Rubin BR, Burton R, Navarra S, et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004; 50:598.</a></li><li><a class="nounderline abstract_t">Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin 1991; 12:423.</a></li><li><a class="nounderline abstract_t">Lomen PL, Turner LF, Lamborn KR, et al. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986; 80:134.</a></li><li><a class="nounderline abstract_t">Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15:1422.</a></li><li><a class="nounderline abstract_t">Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312.</a></li><li><a class="nounderline abstract_t">van Durme CM, Wechalekar MD, Buchbinder R, et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; :CD010120.</a></li><li><a class="nounderline abstract_t">Fravel MA, Ernst ME. Management of gout in the older adult. Am J Geriatr Pharmacother 2011; 9:271.</a></li><li><a class="nounderline abstract_t">Stamp LK, Jordan S. The challenges of gout management in the elderly. Drugs Aging 2011; 28:591.</a></li><li><a class="nounderline abstract_t">Singh H, Torralba KD. Therapeutic challenges in the management of gout in the elderly. Geriatrics 2008; 63:13.</a></li><li><a class="nounderline abstract_t">By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2019; 67:674.</a></li><li><a class="nounderline abstract_t">Usta M, Ersoy A, Ayar Y, et al. Comparison of endoscopic and pathological findings of the upper gastrointestinal tract in transplant candidate patients undergoing hemodialysis or peritoneal dialysis treatment: a review of literature. BMC Nephrol 2020; 21:444.</a></li><li><a class="nounderline abstract_t">Simmonds HA, Cameron JS, Goldsmith DJ, et al. Familial juvenile hyperuricaemic nephropathy is not such a rare genetic metabolic purine disease in Britain. Nucleosides Nucleotides Nucleic Acids 2006; 25:1071.</a></li><li><a class="nounderline abstract_t">Lhotta K, Gehringer A, Jennings P, et al. Familial juvenile hyperuricemic nephropathy: report on a new mutation and a pregnancy. Clin Nephrol 2009; 71:80.</a></li><li><a class="nounderline abstract_t">van Veen TR, Haeri S. Gout in pregnancy: a case report and review of the literature. Gynecol Obstet Invest 2015; 79:217.</a></li><li><a class="nounderline abstract_t">Rabinovitch O, Zemer D, Kukia E, et al. Colchicine treatment in conception and pregnancy: two hundred thirty-one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol 1992; 28:245.</a></li><li><a class="nounderline abstract_t">Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36:2921.</a></li><li><a class="nounderline abstract_t">Ben-Chetrit E, Scherrmann JM, Levy M. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum 1996; 39:1213.</a></li><li><a class="nounderline abstract_t">Hui M, Carr A, Cameron S, et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford) 2017; 56:e1.</a></li><li><a class="nounderline abstract_t">Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237.</a></li><li><a class="nounderline abstract_t">Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al. Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford) 2019.</a></li><li><a class="nounderline abstract_t">Saag KG, Khanna PP, Keenan RT, et al. A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares. Arthritis Rheumatol 2021; 73:1533.</a></li><li><a class="nounderline abstract_t">Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71:1839.</a></li><li><a class="nounderline abstract_t">So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62:3064.</a></li></ol></div><div id="topicVersionRevision">Topic 1666 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36383714" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23024029" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27802508" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27457514" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2016 updated EULAR evidence-based recommendations for the management of gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10529162" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633379" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Intra-articular glucocorticoids for acute gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18514729" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17276548" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903390" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24472084" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425920" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systemic corticosteroids for acute gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16632483" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2196674" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Systemic steroid therapy for acute gout: a clinical trial and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32741131" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3314832" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Does colchicine work? The results of the first controlled study in acute gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20131255" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31666237" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20224523" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Colchicine and other drugs for gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973929" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Colchicine update: 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18973929" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Colchicine update: 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007523" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21169852" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13673086" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14060403" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mutual suppression of the uricosuric effects of sulfinpyrazone and salicylate: A study in interactions between drugs</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10643705" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17125112" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Renal effects of low dose aspirin in elderly patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23345599" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Low-dose aspirin use and recurrent gout attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22859357" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077033" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14872504" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1838075" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3963020" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Flurbiprofen in the treatment of acute gout. A comparison with indomethacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3058974" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707532" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25225849" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Non-steroidal anti-inflammatory drugs for acute gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21849262" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Management of gout in the older adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21812496" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The challenges of gout management in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18593209" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Therapeutic challenges in the management of gout in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30693946" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : American Geriatrics Society 2019 Updated AGS Beers Criteria®for Potentially Inappropriate Medication Use in Older Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33092560" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Comparison of endoscopic and pathological findings of the upper gastrointestinal tract in transplant candidate patients undergoing hemodialysis or peritoneal dialysis treatment: a review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17065066" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Familial juvenile hyperuricaemic nephropathy is not such a rare genetic metabolic purine disease in Britain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19203555" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Familial juvenile hyperuricemic nephropathy: report on a new mutation and a pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25660596" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Gout in pregnancy: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1285892" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Colchicine treatment in conception and pregnancy: two hundred thirty-one pregnancies in patients with familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320112" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8670333" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Colchicine in breast milk of patients with familial Mediterranean fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28549177" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The British Society for Rheumatology Guideline for the Management of Gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16407889" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Gout-associated uric acid crystals activate the NALP3 inflammasome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30602035" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33605029" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22586173" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20533546" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
